ClinicalTrials.gg
CompletedNCT00976235Updated Nov 12, 2026

A Long-Term Monitoring Study of the IMT-002 Patients

An interventional study of IMT - Implantable Miniature Telescope in Macular Degeneration, sponsored by VisionCare, Inc.. Completed at 28 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..

Enrollment
Largest of 10
129 · median 31
Started
2006
the only one that year
No phase
9 of 10
2 open now
Registered
2nd of 10
by date

Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one has the largest enrollment, is the only one that started in 2006, is one of 9 with no phase, and was the 2nd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Macular Degeneration by VisionCare, Inc., or all of them as a file.
02

Study summary

This is a 5-year study of patients implanted with the Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) under Protocol IMT-002. All patients implanted with the telescope prosthesis who enrolled in the IMT-002 trial were asked to participate in this study to monitor long-term safety. Patients will undergo examinations at six-month intervals up to a total of 5 years following implantation.

Read the detailed description

Every 6 months, manifest refraction, visual acuity, intraocular pressure, slit lamp examination, endothelial cell density, device failures, complications and adverse events will be assessed.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Macular Degeneration
  • Visual Impairment
  • Quality of Life
  • Telescope Prosthesis
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have participated in the IMT-002 trial.
  • Patients must be able to understand and comply with the requirements of the clinical study, and be able to abide by the requirements and restrictions of the study.
  • Patients must be able to provide voluntary , and must sign and be given a copy of the written Informed Consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients who have not participated in the IMT-002 trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    IMT

    Device: IMT - Implantable Miniature Telescope

Interventions

  • DeviceIMT - Implantable Miniature Telescope

    Implantation of the telescope prosthesis (performed under the initial study)

06

What researchers measure

Primary outcomes

  1. Long term safety (Intraocular pressure, Slit lamp, Endothelial Cell Density, Visual Acuity, Complications, Adverse Events and Device Failures)

    Time frame: 5 years from implantation

07

Study locations

28 sites
  • Retina Centers P.C.
    Tucson, Arizona 85704, United States
  • University of California at Irvine
    Irvine, California 92697, United States
  • Altos Eye Physician
    Los Altos, California 94024, United States
  • Doheny Retina Institute - University of Southern California
    Los Angeles, California 90033, United States
  • Sarasota Retinal Institute
    Sarasota, Florida 34239, United States
  • Emory Eye Center
    Atlanta, Georgia 30322, United States
  • Kraft Eye Institute
    Chicago, Illinois 60634, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Wilmer Ophthalmological Institute
    Baltimore, Maryland 21287-9277, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Massachusetts Eye & Ear Infirmary
    Boston, Massachusetts 02114, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • W.K. Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Associated Retinal Consultants
    Royal Oak, Michigan 48073, United States
  • Associated Eye Care
    Stillwater, Minnesota 55082, United States
  • Discover Vision Centers
    Independence, Missouri 64055, United States
  • Manhattan Eye & Ear
    New York, New York 10021, United States
  • Southeast Clinical Research
    Charlotte, North Carolina 28210, United States
  • Duke University Eye Center
    Durham, North Carolina 27710, United States
  • Retina Associates of Cleveland
    Beachwood, Ohio 44122, United States
  • Dean A. McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Fine, Hoffman & Packer
    Eugene, Oregon 97401, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Vitreoretinal Foundation
    Memphis, Tennessee 78240, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Medical Center Ophthalmology
    San Antonio, Texas 78240, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2009
First posted
Sep 14, 2009
Start
Jun 2006
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00976235
Lead sponsor
VisionCare, Inc.
Responsible party
Sponsor
First posted
Sep 14, 2009
Start date
Jun 2006
Primary completion
May 2011
Completion
May 2011
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion